WHO Pharmaceuticals Newsletter No. 4, 2014

OMS, 29 de septiembre 2014

Tabla de contenidos

Regulatory Matters

Azathioprine ................................................................................... 4

Docetaxel ....................................................................................... 4

Etonogestrel/ethinyl estradiol slow release vaginal ring ................. 4

Lidocaine Viscous ............................................................................ 4

Methadone (Oral) ............................................................................. 5

Ondansetron .................................................................................... 5

Renin-Angiotensin system (RAS) acting agents ................................ 6

Serotonin Antagonists ...................................................................... 6

Strontium ranelate ........................................................................... 7

Testosterone products ...................................................................... 7

Safety of Medicines

Chlorhexidine solution ...................................................................... 9

Ferumoxytol ...................................................................................... 9

Intravenous dantrolene ..................................................................... 9

Ivabradine ....................................................................................... 10

Meningococcal B Vaccine ................................................................. 10

Meso-2, 3-dimercaptosuccinic acid................................................... 10

Ofatumumab..................................................................................... 11

Fentanyl “patches”............................................................................ 11

Vaccines ....................................................................................... …..11

Voriconazole ...................................................................................... 12

Zolpidem ...................................................................................... …..12

Signal

Agomelatine and Hypotension ......................................................... 13

Dronedarone and Polyneuropathy .................................................... 19

Finasteride and Convulsions ............................................................ 23

Roflumilast and Pneumonia ............................................................. 29

Response from Takeda and Forest Laboratories ................................. 34

disponible en

http://bit.ly/1vxBUvD